1160221-26-0

Basic information

• Product Name: 3-(6-{[1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoicacidhydrochloride
• Synonyms: 3-(6-{[1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoicacidhydrochloride;Benzoic acid, 3-[6-[[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]aMino]-3-Methyl-2-pyridinyl]-, hydrochloride (1:1);3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxaMido)-3-Methylpyridin-2-yl)benzoic acid hydrochlorid;3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzo;3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxaMido)-3-Methylpyridin-2-yl)benzoic acid hydrochloride;3-[6-[[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]benzoic acid hydrochloride (1:1);Lumacaftor hydrochloride;Lumacaftor HCl
• CAS NO: 1160221-26-0
• Molecular Formula: C₂₄H₁₈F₂N₂O₅*ClH
• Molecular Weight: 488.8678664
• Mol File: 1160221-26-0.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(6-{[1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoicacidhydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(6-{[1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoicacidhydrochloride(1160221-26-0)
• EPA Substance Registry System: 3-(6-{[1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoicacidhydrochloride(1160221-26-0)

Safety Data

• Hazardous Substances Data: 1160221-26-0(Hazardous Substances Data)

Usage

General Description

3-(6-{[1-(2,2-Difluoro-benzo[1,3]dioxol-5-yl)-cyclopropanecarbonyl]-amino}-3-methyl-pyridin-2-yl)-benzoicacidhydrochloride is a chemical compound that contains a benzoic acid hydrochloride group. It also has a complex structure consisting of a 3-methyl-pyridin-2-yl, cyclopropanecarbonyl, and difluoro-benzo[1,3]dioxol-5-yl moieties. The compound is likely used in pharmaceutical or research applications due to its intricate and specific structure, which may have biological activity or therapeutic potential. The hydrochloride salt form also suggests that it is a water-soluble compound that may be used in aqueous formulations.

Upstream product

• 3430-17-9 2-bromo-3-picoline 
• 1083057-12-8 tert-butyl 3-(3-methylpyridin-2-yl)benzoate 
• 1083057-13-9 tert-butyl 3-(3-methyl-1-oxo-1λ-pyridin-2-yl)benzoate 
• 1083057-14-0 tert-butyl 3-(6-amino-3-methylpyridin-2-yl)benzoate 
• 89466-17-1 6-amino-2-bromo-3-methylpyridine 
• 19230-57-0 2-bromo-3-methylpyridine 1-oxide 
• 25487-66-5 3-Carboxyphenylboronic acid 
• 773873-95-3 2,2-difluorobenzo[1,3]dioxole-5-carboxylic acid methyl ester 
• 1004294-65-8 1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)cyclopropane carboxylic acid chloride 
• 476473-97-9 5-chloromethyl-2,2-difluoro-benzo[1,3]dioxole 
• 72768-97-9 (2,2-difluoro-1,3-benzodioxol-5-yl)methanol 
• 220210-56-0 3-(tert-butoxycarbonyl)phenylboronic acid 
• 862574-88-7 1-(2,2-difluorobenzo[1,3]dioxol-5-yl)cyclopropane-1-carboxylic acid 
• 656-46-2 2,2-difluoro-1,3-benzodioxole-5-carboxylic acid 

Downstream Products

• 936727-05-8 Lumacaftor 

Relevant articles and documents

METHODS OF TREATMENT FOR CYSTIC FIBROSIS

This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.

PROCESS FOR PREPARATION OF LUMACAFTOR

The present invention relates to a process for the preparation of amorphous lumacaftor. The present invention relates to a process for the preparation of intermediate 6-amino-2- halo-3-methylpyridine compounds used in the preparation of lumacaftor. The present invention relates to lumacaftor hydrobromide, process for its preparation and conversion thereof to lumacaftor.

PROCESS OF PREPARING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES

Processes of preparing pharmaceutical compositions comprising 3-(6-(1-(2,2- difluorobenzo[d][1,3] dioxol-5 -yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5- hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of administering, and kits thereof are disclosed.